On November 1, 2009, Taiwan began a nationwide pandemic A(H1N1) 2009 vaccine ("H1N1 vaccine") program to control the influenza pandemic. Timely assessment of immunization safety during this mass vaccination campaign was a public health priority. Therefore, the government developed a national postlicensure safety surveillance strategy to identify and evaluate new, unexpected, or prioritized adverse events in recipients of H1N1 vaccine in near real-time. We describe the design and methodology of this new safety assessment infrastructure, address challenges encountered, and its potential future use for routine vaccine pharmacovigilance in Taiwan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2010.08.069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A?
Heliyon
December 2024
Virology Laboratory, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, (icddr,b), Bangladesh.
According to sparse information from various countries, the seasonal influenza virus circulation has drastically decreased during the COVID-19 pandemic. Here, we show the cross-reactivity of anti-SARS-CoV-2 antibodies against influenza viruses. Plasma samples were collected from 311 SARS-CoV-2 infected individuals.
View Article and Find Full Text PDFConsortium of 'consistent amino acid substitutions' on influenza A (H1N1) viral proteins emerged at specific stages of viral infection: a big data analysis.
J Biomol Struct Dyn
December 2024
Department of Biological Sciences, Birla Institute of Technology and Science, Pilani, Hyderabad, India.
Influenza A (H1N1) virus has been one of the most common threats to humankind since 1918. The viral genome is frequently substituted, leading to new strains and recurrent pandemics. Despite knowing the effects of single amino acid substitutions on individual viral proteins, the effects of collective substitutions on viral infection remain elusive.
View Article and Find Full Text PDFThe 1978 English boarding school influenza outbreak: where the classic SEIR model fails.
J R Soc Interface
November 2024
Department of Applied Mathematics, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.
Previous work has failed to fit classic SEIR epidemic models satisfactorily to the prevalence data of the famous English boarding school 1978 influenza A/H1N1 outbreak during the children's pandemic. It is still an open question whether a biologically plausible model can fit the prevalence time series and the attack rate correctly. To construct the final model, we first used an intentionally very flexible and overfitted discrete-time epidemiologic model to learn the epidemiological features from the data.
View Article and Find Full Text PDFNational Influenza Annual Report 2023-2024: A focus on influenza B and public health implications.
Can Commun Dis Rep
November 2024
National Microbiology Laboratory Branch, Public Health Agency of Canada, Winnipeg, MB.
Article Synopsis
- The 2023-2024 influenza epidemic started in week 45, primarily driven by influenza A(H1N1), but by week 14, influenza B/Victoria became the dominant strain as influenza A cases decreased.
- A significant portion of influenza B cases affected younger populations, with over half of detections and nearly half of hospitalizations occurring in children aged 0-19.
- The ongoing discussion about the removal of the influenza B/Yamagata strain from vaccines highlights the need for surveillance to prepare for new seasonal patterns driven by influenza B/Victoria.
The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated Pediatric Influenza Patients during Two Influenza Seasons after the COVID-19 Pandemic: The Impact of Comorbidities on Hospitalization for Influenza in Children.
Viruses
October 2024
Faculty of Medicine, University of Medicine and Pharmacy, "Carol Davila", No. 37, Dionisie Lupu Street, 2nd District, 020021 Bucharest, Romania.
Antiviral therapy such as oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza for almost 20 years. The therapy is officially authorized for newborns two weeks of age or older, however, questions about its safety and effectiveness still surround it. Our goals were to assess the epidemiological features of two consecutive seasonal influenza cases in children following the COVID-19 pandemic; to observe the clinical effectiveness and tolerability of oseltamivir in hospitalized children who were not vaccinated against influenza and had different influenza subtypes, including A(H1N1), A(H3N2), and B; and to identify specific comorbidities associated with influenza in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!